Pharma Mar, S.A. (PHMMF)

Other OTC - Other OTC Delayed Price. Currency in USD

69.40

0.00

(0.00%)

At close: 11:02AM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Neutralpattern detected

View all chart patterns

Performance Outlook

Previous Close	69.40
Open	69.40
Bid	0.00 x 0
Ask	0.00 x 0
Day's Range	69.40 - 69.40
52 Week Range	50.85 - 79.38
Volume	37
Avg. Volume	11

Market Cap	1.257B
Beta (5Y Monthly)	0.13
PE Ratio (TTM)	23.61
EPS (TTM)	2.94
Earnings Date	N/A
Forward Dividend & Yield	0.65 (0.94%)
Ex-Dividend Date	Jul 13, 2022
1y Target Est	N/A

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

N/A

Subscribe to Yahoo Finance Plus to view Fair Value for PHMMF

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

PHARMA MAR SA
Analyst Report: MERCK Kommanditgesellschaft auf AktienMerck KGaA operates in three main segments: life sciences, performance materials, and healthcare. The life sciences segment (46% of 2021 sales) provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. In the healthcare segment (36%), Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In its electronics segment (18%), the company offers specialty materials to manufacture a variety of products, such as semiconductors, flat-screen televisions, automobiles, and cosmetics. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
Rating
Fair Value
Economic Moat
7 days agoMorningstar